Since late 2024, there has been a global shortage of Pegasys, the interferon medicine used by many people living with MPNs. This is due to delays in building a new manufacturing site and gaining the necessary approvals.
In the UK, the NHS arranged for patients to be prescribed Besremi as an alternative interferon. Besremi has been safely and effectively used during this time.
The MHRA (Medicines & Healthcare products Regulatory Agency) has recently approved a new manufacturing site to produce and distribute Pegasys. This is a positive step, but no details have been shared yet on how much Pegasys will be available or when it will reach pharmacies. We are working with NHS England to understand how they will support us in managing patients’ interferon supplies, including decisions around which formulations will be available.
MPN Voice will shortly be launching a survey to gather feedback on patients’ experiences during the Pegasys shortage, including access to and experience of Besremi.
Please speak with your clinical team if you have any questions about your treatment.
MPN Voice will continue to monitor the situation and provide updates.
